Last viewed: RETA

Prices are updated after-hours

RETA Nasdaq 2021 - 04 - 30

Reata Pharmaceuticals, Inc.

RETA | $172.36 0.02% 0.03% 0

|

Health Technology

(0.0% 1d) (0.0% 1m) (71.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (165.53% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 5,789,158,047
http://www.reatapharma.com
Sec Filling | Patents | 220 employees

(US) Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.

education

add to watch list Paper trade email alert is off

Press-releases

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
CNSP A | $0.1975 -3.38% -3.49% 130K

|

Health Technology

| -71.06% | O: 5.82% H: 7.57% C: -7.32%
berubicin treatment pharmaceuticals glioblastoma study

Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics
Published: 2024-01-10 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

|

Health Technology

| -10.95% | O: 1.1% H: 0.0% C: 0.0%
NVO | News | $122.75 -1.43% 0.0% 2.8M

|

Health Technology

| 14.59% | O: -0.33% H: 0.35% C: -1.5%
LLY | News | $745.95 -0.64% -0.1% 1.7M

|

Health Technology

| 19.13% | O: 0.67% H: 0.85% C: 0.21%
SNY | News | $45.395 -1.55% -1.58% 4.4M

|

Health Technology

| -11.29% | O: 0.69% H: 0.0% C: 0.0%
ALDX 4 | $3.99 0.5% 0.5% 430K

|

Health Technology

| 15.87% | O: -1.8% H: 0.46% C: -2.44%
companies therapeutics growth market

Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock
Published: 2024-01-08 (Crawled : 13:00) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0

|

Health Technology

| Email alert Add to watchlist

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Published: 2023-11-22 (Crawled : 15:00) - biospace.com/
CNSP A | $0.1975 -3.38% -3.49% 130K

|

Health Technology

| -90.02% | O: 3.35% H: 25.0% C: 4.17%
berubicin ongoing pharmaceuticals study

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published: 2023-11-07 (Crawled : 15:00) - biospace.com/
ABBV | $164.69 0.27% 0.0% 4.5M

|

Health Technology

| 15.61% | O: -0.28% H: 0.0% C: 0.0%
SMMT A | $3.51 -1.68% -1.71% 1.2M

|

Health Technology

| 63.76% | O: -0.46% H: 6.68% C: -11.75%
PLSE | $7.37 -1.34% -1.36% 150K

|

Health Technology

| 43.93% | O: 0.39% H: 6.43% C: 1.92%
BIIB | $190.55 -0.84% -0.84% 1.5M

|

Health Technology

| -21.51% | O: -0.82% H: 0.73% C: -0.4%
ALNY | $145.045 -0.19% -0.19% 400K

|

Health Technology

| -12.22% | O: 1.06% H: 2.42% C: 0.76%
therapeutics financial results

CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
CNSP A | $0.1975 -3.38% -3.49% 130K

|

Health Technology

| -80.51% | O: -2.8% H: 18.26% C: 13.46%
rapid berubicin treatment ongoing glioblastoma study

Biogen Completes Acquisition of Reata Pharmaceuticals
Published: 2023-09-26 (Crawled : 13:00) - globenewswire.com
BIIB | $190.55 -0.84% -0.84% 1.5M

|

Health Technology

| -23.48% | O: -0.02% H: 1.37% C: 1.21%
acquisition pharmaceuticals

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Published: 2023-08-14 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0

|

Health Technology

| 2.91% | O: 0.31% H: 1.04% C: 0.76%
CNSP A | $0.1975 -3.38% -3.49% 130K

|

Health Technology

| -89.73% | O: -2.46% H: 2.53% C: -10.61%
berubicin pharmaceuticals therapy results study

CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0

|

Health Technology

| 3.77% | O: 0.07% H: 0.83% C: 0.57%
CNSP A | $0.1975 -3.38% -3.49% 130K

|

Health Technology

| -90.26% | O: 0.93% H: 3.24% C: 1.39%
berubicin update treatment ongoing pharmaceuticals trial glioblastoma study

Biogen to Acquire Reata Pharmaceuticals
Published: 2023-07-28 (Crawled : 11:00) - globenewswire.com
RETA | $172.36 0.02% 0.03% 0

|

Health Technology

| 58.78% | O: 51.72% H: 1.55% C: 1.52%
BIIB | $190.55 -0.84% -0.84% 1.5M

|

Health Technology

| -25.74% | O: 0.19% H: 1.88% C: 0.73%
pharmaceuticals acquire

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000905148-23-001010	4	2023-09-26	2023-09-26	Sell	D	6000	0
0000905148-23-001010	4	2023-09-26	2023-09-26	Sell	D	6300	0
0000905148-23-001010	4	2023-09-26	2023-09-26	Sell	D	1692857	0
0000905148-23-001010	4	2023-09-26	2023-09-26	Sell	D	25004	0

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

66%

34%

Top 10 Gainers

AGBA | $1.02 155.0% 60.78% 120M

|

INVO | $1.555 104.6% 51.13% 5M

|

Health Technology

ISPC | $0.437 105.16% 49.53% 37M

|

Professional, Scientific, and T...

WLGS | $0.92 84.0% 45.65% 900K

|

OST | $0.499 21.38% 45.26% 1.9M

|

ZCMD | $2.44 78.1% 43.85% 330K

|

Commercial Services

XPON | $3.1 60.62% 37.74% 16M

|

TIRX | $0.7 44.39% 30.74% 58M

|

BNTC | $6.92 44.17% 30.64% 3.5M

|

Health Technology

GGE | $0.035 19.86% 29.3% 64M

|

Last 48 Hours Insiders Buying

AXR P 2400 | $22.17 2.69% 0.0% 5.5K

|

| 21:00
FAST P 3350 | $67.5 -1.43% -1.45% 3.6M

|

Distribution Services

| 20:00
QCRH | $55.405 1.33% 1.31% 54K

|

| 18:01
RVP P 15363 | $1.05 0.96% 0.0% 120K

|

Health Technology

| 18:00
VUZI | $1.26 3.28% 3.17% 1M

|

Electronic Technology

| 18:00
TPL P 3 | $582.4 -0.44% 0.0% 63K

|

| 15:00
RELL | $10.15 2.94% 2.86% 94K

|

Electronic Technology

| 13:30
IZEA | $2.65 4.74% 4.53% 31K

|

Technology Services

| 00:00
RKT P 383 | $11.53 1.32% 0.0% 1.6M

|

| 22:30
CTRN P 18090 | $22.28 -0.4% -0.4% 55K

|

| 22:00
BRN P 10650 | $2.8 0.36% -0.36% 54K

|

Energy Minerals

| 21:00
NEOG P 10000 | $11.94 -1.65% -1.68% 2.9M

|

Health Technology

| 16:30
RMCF | $3.61 2.27% 2.22% 18K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar